Capital Investment Advisors LLC Sells 4,807 Shares of Zoetis Inc. $ZTS

Capital Investment Advisors LLC reduced its stake in Zoetis Inc. (NYSE:ZTS) by 34.0% in the fourth quarter, Holdings Channel.com reports. The fund owned 9,335 shares of the company’s stock after selling 4,807 shares during the period. Capital Investment Advisors LLC’s holdings in Zoetis were worth $1,174,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. CIBC Asset Management Inc increased its position in shares of Zoetis by 4.3% during the third quarter. CIBC Asset Management Inc now owns 251,495 shares of the company’s stock valued at $36,745,000 after buying an additional 10,434 shares during the period. Mitsubishi UFJ Trust & Banking Corp boosted its position in shares of Zoetis by 6.5% in the third quarter. Mitsubishi UFJ Trust & Banking Corp now owns 295,482 shares of the company’s stock valued at $43,235,000 after acquiring an additional 18,040 shares during the period. Ninety One UK Ltd grew its stake in Zoetis by 19.6% during the third quarter. Ninety One UK Ltd now owns 1,119,132 shares of the company’s stock valued at $163,751,000 after acquiring an additional 183,686 shares in the last quarter. Quilter Plc increased its holdings in Zoetis by 10.2% during the 3rd quarter. Quilter Plc now owns 438,959 shares of the company’s stock worth $64,228,000 after acquiring an additional 40,615 shares during the period. Finally, CWM LLC increased its holdings in Zoetis by 53.2% during the 3rd quarter. CWM LLC now owns 55,040 shares of the company’s stock worth $8,053,000 after acquiring an additional 19,118 shares during the period. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Stock Up 0.1%

ZTS opened at $113.48 on Monday. Zoetis Inc. has a 12 month low of $113.29 and a 12 month high of $172.23. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The business’s 50-day moving average price is $123.39 and its 200-day moving average price is $129.03. The company has a market cap of $47.90 billion, a P/E ratio of 18.85, a P/E/G ratio of 1.73 and a beta of 0.95.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. The company had revenue of $2.39 billion during the quarter, compared to analysts’ expectations of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.Zoetis’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same period in the prior year, the business posted $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, equities analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be paid a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio is 35.22%.

Analyst Upgrades and Downgrades

Several brokerages have commented on ZTS. Weiss Ratings downgraded shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday. UBS Group set a $136.00 price target on shares of Zoetis in a report on Thursday, January 29th. Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. HSBC set a $140.00 price objective on Zoetis in a research note on Wednesday, December 10th. Finally, The Goldman Sachs Group upgraded Zoetis to a “buy” rating in a research report on Monday, December 15th. Six investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Zoetis has an average rating of “Hold” and an average target price of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.